Literature DB >> 35145225

METTL16 exerts an m6A-independent function to facilitate translation and tumorigenesis.

Rui Su1, Lei Dong2, Yangchan Li2,3, Min Gao2,4, P Cody He5,6, Wei Liu2,7, Jiangbo Wei5,6, Zhicong Zhao2,8, Lei Gao2, Li Han2,9, Xiaolan Deng2, Chenying Li2,10, Emily Prince2, Brandon Tan2, Ying Qing2, Xi Qin2, Chao Shen2, Meilin Xue2, Keren Zhou2, Zhenhua Chen2, Jianhuang Xue2, Wei Li2, Hanjun Qin11, Xiwei Wu11, Miao Sun12, Yunsun Nam13, Chun-Wei Chen2,14, Wendong Huang15,16, David Horne14,17, Steven T Rosen14,18,19, Chuan He20,21, Jianjun Chen22,23,24.   

Abstract

METTL16 has recently been identified as an RNA methyltransferase responsible for the deposition of N6-methyladenosine (m6A) in a few transcripts. Whether METTL16 methylates a large set of transcripts, similar to METTL3 and METTL14, remains unclear. Here we show that METTL16 exerts both methyltransferase activity-dependent and -independent functions in gene regulation. In the cell nucleus, METTL16 functions as an m6A writer to deposit m6A into hundreds of its specific messenger RNA targets. In the cytosol, METTL16 promotes translation in an m6A-independent manner. More specifically, METTL16 directly interacts with the eukaryotic initiation factors 3a and -b as well as ribosomal RNA through its Mtase domain, thereby facilitating the assembly of the translation-initiation complex and promoting the translation of over 4,000 mRNA transcripts. Moreover, we demonstrate that METTL16 is critical for the tumorigenesis of hepatocellular carcinoma. Collectively, our studies reveal previously unappreciated dual functions of METTL16 as an m6A writer and a translation-initiation facilitator, which together contribute to its essential function in tumorigenesis.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35145225      PMCID: PMC9070413          DOI: 10.1038/s41556-021-00835-2

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN: 1465-7392            Impact factor:   28.213


  58 in total

Review 1.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.

Authors:  Huilin Huang; Hengyou Weng; Jianjun Chen
Journal:  Cancer Cell       Date:  2020-03-16       Impact factor: 31.743

2.  Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex.

Authors:  Xiang Wang; Jing Feng; Yuan Xue; Zeyuan Guan; Delin Zhang; Zhu Liu; Zhou Gong; Qiang Wang; Jinbo Huang; Chun Tang; Tingting Zou; Ping Yin
Journal:  Nature       Date:  2016-05-25       Impact factor: 49.962

3.  Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases.

Authors:  Ping Wang; Katelyn A Doxtader; Yunsun Nam
Journal:  Mol Cell       Date:  2016-06-30       Impact factor: 17.970

Review 4.  RNA modifications modulate gene expression during development.

Authors:  Michaela Frye; Bryan T Harada; Mikaela Behm; Chuan He
Journal:  Science       Date:  2018-09-28       Impact factor: 47.728

5.  A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation.

Authors:  Jianzhao Liu; Yanan Yue; Dali Han; Xiao Wang; Ye Fu; Liang Zhang; Guifang Jia; Miao Yu; Zhike Lu; Xin Deng; Qing Dai; Weizhong Chen; Chuan He
Journal:  Nat Chem Biol       Date:  2013-12-06       Impact factor: 15.040

6.  Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase.

Authors:  Xiao-Li Ping; Bao-Fa Sun; Lu Wang; Wen Xiao; Xin Yang; Wen-Jia Wang; Samir Adhikari; Yue Shi; Ying Lv; Yu-Sheng Chen; Xu Zhao; Ang Li; Ying Yang; Ujwal Dahal; Xiao-Min Lou; Xi Liu; Jun Huang; Wei-Ping Yuan; Xiao-Fan Zhu; Tao Cheng; Yong-Liang Zhao; Xinquan Wang; Jannie M Rendtlew Danielsen; Feng Liu; Yun-Gui Yang
Journal:  Cell Res       Date:  2014-01-10       Impact factor: 25.617

Review 7.  RNA N6-methyladenosine modification in cancers: current status and perspectives.

Authors:  Xiaolan Deng; Rui Su; Hengyou Weng; Huilin Huang; Zejuan Li; Jianjun Chen
Journal:  Cell Res       Date:  2018-04-23       Impact factor: 25.617

8.  mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis.

Authors:  Junho Choe; Shuibin Lin; Wencai Zhang; Qi Liu; Longfei Wang; Julia Ramirez-Moya; Peng Du; Wantae Kim; Shaojun Tang; Piotr Sliz; Pilar Santisteban; Rani E George; William G Richards; Kwok-Kin Wong; Nicolas Locker; Frank J Slack; Richard I Gregory
Journal:  Nature       Date:  2018-09-19       Impact factor: 49.962

9.  The interactome of a family of potential methyltransferases in HeLa cells.

Authors:  Valentina V Ignatova; Pascal W T C Jansen; Marijke P Baltissen; Michiel Vermeulen; Robert Schneider
Journal:  Sci Rep       Date:  2019-04-29       Impact factor: 4.379

10.  Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites.

Authors:  Schraga Schwartz; Maxwell R Mumbach; Marko Jovanovic; Tim Wang; Karolina Maciag; G Guy Bushkin; Philipp Mertins; Dmitry Ter-Ovanesyan; Naomi Habib; Davide Cacchiarelli; Neville E Sanjana; Elizaveta Freinkman; Michael E Pacold; Rahul Satija; Tarjei S Mikkelsen; Nir Hacohen; Feng Zhang; Steven A Carr; Eric S Lander; Aviv Regev
Journal:  Cell Rep       Date:  2014-06-26       Impact factor: 9.423

View more
  24 in total

1.  METTL3 preferentially enhances non-m6A translation of epigenetic factors and promotes tumourigenesis.

Authors:  Xueju Wei; Yue Huo; Jingnan Pi; Yufeng Gao; Shuan Rao; Manman He; Qinglv Wei; Peng Song; Yiying Chen; Dongxu Lu; Wei Song; Junbo Liang; Lingjie Xu; Haixia Wang; Guolin Hong; Yuehong Guo; Yanmin Si; Jiayue Xu; Xiaoshuang Wang; Yanni Ma; Shuyang Yu; Dongling Zou; Jing Jin; Fang Wang; Jia Yu
Journal:  Nat Cell Biol       Date:  2022-08-04       Impact factor: 28.213

Review 2.  METTLing in Stem Cell and Cancer Biology.

Authors:  John G Tooley; James P Catlin; Christine E Schaner Tooley
Journal:  Stem Cell Rev Rep       Date:  2022-09-12       Impact factor: 6.692

3.  Alternative splicing of METTL3 explains apparently METTL3-independent m6A modifications in mRNA.

Authors:  Hui Xian Poh; Aashiq H Mirza; Brian F Pickering; Samie R Jaffrey
Journal:  PLoS Biol       Date:  2022-07-19       Impact factor: 9.593

Review 4.  The Key Role of RNA Modification in Breast Cancer.

Authors:  Yang Liu; Tong Zhu; Yi Jiang; Jiawen Bu; Xudong Zhu; Xi Gu
Journal:  Front Cell Dev Biol       Date:  2022-06-01

Review 5.  Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application.

Authors:  Fusheng Zhang; Haiyang Liu; Meiqi Duan; Guang Wang; Zhenghou Zhang; Yutian Wang; Yiping Qian; Zhi Yang; Xiaofeng Jiang
Journal:  J Hematol Oncol       Date:  2022-07-06       Impact factor: 23.168

Review 6.  The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma.

Authors:  Fan Chen; Xuan Xie; Min Chao; Haiyan Cao; Liang Wang
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

Review 7.  Effects of N6-Methyladenosine Modification on Cancer Progression: Molecular Mechanisms and Cancer Therapy.

Authors:  Yong-Fu Zhu; Shu-Jie Wang; Jie Zhou; Ye-Han Sun; You-Mou Chen; Jia Ma; Xing-Xing Huo; Hang Song
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

8.  METTL16 promotes hepatocellular carcinoma progression through downregulating RAB11B-AS1 in an m6A-dependent manner.

Authors:  Yun-Zhang Dai; Yong-da Liu; Jie Li; Mei-Ting Chen; Mei Huang; Fang Wang; Qing-Song Yang; Ji-Hang Yuan; Shu-Han Sun
Journal:  Cell Mol Biol Lett       Date:  2022-05-20       Impact factor: 8.702

Review 9.  The Emerging Role of N6-Methyladenosine RNA Methylation as Regulators in Cancer Therapy and Drug Resistance.

Authors:  Zhaolin Chen; Ying Hu; Le Jin; Fan Yang; Haiwen Ding; Lei Zhang; Lili Li; Tingting Pan
Journal:  Front Pharmacol       Date:  2022-04-06       Impact factor: 5.988

10.  Relevance of RNA N6-Methyladenosine Regulators for Pulmonary Fibrosis: Implications for Chronic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis.

Authors:  Yiyi Zhou; Chen Fang; Qinying Sun; Yuchao Dong
Journal:  Front Genet       Date:  2022-07-14       Impact factor: 4.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.